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Summary. Utilising a specific monoclonal mouse 
antibody (E9), metallothionein (MT) expression has 
been immunohistochemically investigated in 112 
formalin-fixed paraffin-embedded surgical gastric 
samples, 38 of which were early carcinomas (EGC) and 
74 advanced ones (AGC); clinico-pathological details 
and follow-up data (ranging from 3 to 197 months, mean 
60.5 months) were available. Eighty-nine portions of 
gastric mucosa adjacent to examined carcinomas 
(transitional mucosa) were also analysed; in addition, 22 
biopsies of normal gastric mucosa were studied as tissue 
control. The MT immunoreactivity was evaluated by 
staining and intensity-distribution scores. A various MT 
positivity was appreciable in the cytoplasm and nucleus 
of antrum or body gastric epithelia1 cells in 100% of 
normal control biopsies. 751112 (67%) gastric 
carcinomas showed MT immunoreactivity with a 
significant lower expression in AGC. No relationships 
were encountered between MT immunostaining and 
clinico-pathological data; in addition, no difference in 
the Kaplan-Meier survival curves of patients with 
various MT expression was achieved. When the 
transitional mucosa was examined, 84/89 (94%) samples 
were stained although the immunoreaction was not 
always concordant with that encountered in adjacent 
carcinomatous elements. The significant statistical 
decrease of MT scores observed by us moving from 
normal to neoplastic gastric mucosa allows us to exclude 
the hypothesis of an overexpression of MT in gastric 
carcinomas. 
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Introduction 
Metallothionein (MT) is a low molecular weight 
protein (6-7 kD) with a high content of cysteinyl 
residues and strong affinity for divalent heavy metal ions 
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such as zinc, copper, cadmium, mercury, silver and 
platinum (Kagi and Nordberg, 1979; Nishimura et al., 
1989). MT is considered to be involved in various 
processes such as storage of essential metals (Webb and 
Cain, 1982; Panemangalore et al., 1983; Schmid et al., 
1993), binding of large amounts of potentially toxic 
metal ions with a sequestration function (Nomiyama et 
al., 1982; Goering and Klaassen, 1984; Nishimura et al., 
1989; Schmid et al., 1993) and scavenging of free 
radicals in tissues and cells (Sato and Bremner, 1993). 
By immunohistochemistry, MT has been demonstrated 
in both the nucleus and the cytoplasm of cells in various 
organs of humans (Savino et al., 1984; Clarkson et al., 
1985; Nartey et al., 1987) and animals (Banerjee et al., 
1982; Danielson et al., 1982; Bataineh et al., 1986; 
Umeyama et al., 1987; Hazelhoff Roelfzema et al., 1989; 
Nishimura et al. ,  1989, 1991; Jasani et al., 1998; 
Fuentealba and Mullins, 1999). 
In human neoplastic pathology (Jasani and Schmid, 
1997), the presence of MT has been immunocyto- 
chemically revealed in testicular embryonal carcinomas 
(Kontozoglou et al., 1987), thyroid tumours (Nartey et 
al., 1987), transitional cell carcinomas of the bladder 
(Bahnson et al., 1991; Siu et al., 1998), in situ and 
invasive breast carcinomas (Fresno et al.. 1993; Schmid 
et al., 1993; Bier et al., 1994; Haerslev et al., 1994; 
Douglas-Jones et al., 1995), cervical intraepithelial and 
invasive squamous carcinomas (McCluggage et al., 
1998) as well as in malignant melanomas (Zelger et al., 
1993), salivary gland tumours (Sunardhi-Widyaputra et 
al., 1995) and hepatocellular (Deng et al., 1998) and 
pancreatic (Ohshio et al., 1996) carcinomas. In addition, 
immunohistochemical evidence of MT has been reported 
in colorectal adenocarcinomas (Ofner et al., 1994; 
Giuffri  et al., 1996), with a variable, not always 
concordant, immunoreactivity in corresponding lymph 
node and distant metastases (Giuffri et al., 1996). On the 
light of these grounds, the aim of the present study was 
to systematically investigate the immunohistochemical 
distribution pattern of MT in the normal gastric mucosa, 
in mucosa adjacent to cancerous tissues as well as in 
gastric carcinomas, either early or advanced. The 
possible correlation between immunohistochemical data 
and morphological characteristics of gastric carcinomas 
as well as the prognostic significance of MT detection 
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have also been investigated. 
Materials and methods 
Surgical samples from 112 patients (60 male, 52 
female; age range 21-84 years, mean age 61.2 yrs) 
resected for gastric carcinoma were included in this 
study: 38 were diagnosed as early gastric carcinoma 
(EGC), while 74 were advanced gastric carcinoma 
(AGC). In 89  samples, a portion of gastric mucosa 
adjacent to carcinomas (transitional mucosa) was 
available for evaluation. The carcinomas were classified 
and staged according to WHO criteria (Watanabe et al., 
1990) and the UICC recommendations (Hermanek and 
Sobin, 1992), respectively; the main clinico-pathological 
data being summarized in Table 1. Preoperative radiation 
andlor chemotherapy were not performed in all cases. 
Data concerning follow-up and cause of death were 
obtained from city registry offices: four patients who 
died during surgery or in the first month of follow-up 
were excluded from the survival study. 
In addition, 22 biopsies of normal gastric mucosa 
(16 from the body and 6 from the antrum) of 16 non- 
neoplastic patients (10 male, 6 female; age range 45-74 
years, mean age 56.4 yrs.) were also analyzed as tissue 
control. 
All samples were fixed in 10% neutral formalin for 
12-24 hrs at room temperature (RT) and then embedded 
in paraffin at 56 "C. From each tissue block, two 
consecutive 3 pm-thick sections were cut and mounted 
on silane-coated glass, then dewaxed in xylene, 
rehydrated in graded ethanols and submitted respectively 
to haematoxylin-eosin stain and to immunohisto- 
chemistry. The immunoreaction was performed utilising 
a monoclonal mouse anti-MT reactive against a single 
and highly conserved epitope shared by the isoforms I 
and I1 (clone E9, commercially obtained from Dako, 
Denmark, w.d. 1:100) applied overnight at 4 T; 
successively, swine anti-mouse globulin antiserum (1:20, 
purchased from Dako, Denmark) and ABC complex for 
30 min at RT and 3,3'-diaminobenzidine tetrahydro- 
chloride-H202 substrate solution for 10 min at RT in 
darkness were applied. Finally, slides were lightly 
counterstained with Mayer's haematoxylin. 
To test the specificity of MT staining, the specific 
MT-E9 antiserum was omitted or replaced by either 
phosphate-buffered saline or normal rabbit serum and 
negative results were obtained. Positive controls were 
represented by normal human kidney. Immunostained 
sections were estimated by light microscopy using a x20 
and x40 objective lens and x10 eyepiece. The 
assessment of immunostained sections was performed on 
a consensus basis by two pathologists (G.T. and G.G.) 
using a double-headed microscope. The percentage of 
stained cells (staining score)  was graded for 
semiquantitative purposes as follows: 0 (no staining); 1 
(>O to 5%); 2 (>5 to 50%); 3 (>50%), as previously 
performed (Giuffrtt et  al., 1996).  In addition, an 
intensity-distribution (ID) score was calculated by 
multiplying, for each case, the staining score by the 
staining intensity (weak=l; moderate=2; strong=3), 
similarly to that elsewhere reported (Douglas-Jones et 
al., 1995; Anstey et al., 1996). 
The possible correlation between immunohisto- 
chemical data and morphological characteristics of 
carcinomas was investigated using non-parametric 
methods (chi-square test, Mann-Whitney U-test, 
Kruskal-Wallis H-test). Survival analysis was performed 
by the Kaplan-Meier method utilising the type of tumour 
as a strata variable and grouping the patients in two 
different manners: the first according to staining score 
values, the second according to ID-score. For the 
comparison of the survival curves, the Mantel-Cox long- 
rank test was used. A P value less than 0.5 was 
considered statistically significant. 
Results 
All samples of normal gastric mucosa showed MT 
positivity variously expressed in the cytoplasm and 
nucleus of antrum and body elements (Fig. 1). In the 
antrum, the staining was localized in the glandular 
mucous cells (6 of 6 cases) as well as in the surface 
mucous cells (4 of 6 cases); in the body, the immuno- 
reactivity was mainly encountered in the lower half of 
the oxyntic glands (15 of 16 cases) and also in the cells 
of the neck zone (15 of 16 cases), while surface mucous 
cells were more rarely stained (5 of 16 cases) (Fig. l). 
The staining and ID-scores relative to normal mucosa 
are reported in Table 2. 
The MT expression observed in 75 of 112 (67%) 
cases of gastric carcinoma is shown in Table 2, with the 
corresponding staining and ID-scores. The positivity was 
localized in the cytoplasm (Fig. 2a),  although a 
combined nuclear/cytoplasmic reactive pattern was also 
seen in neoplastic elements (Fig. 2b,c). In some cases, 
immunoreactive neoplastic cells were found in direct 
contact with negative ones (Fig. 2b-d). The stroma. 
intermingled with neoplastic glands, sometimes showed 
stained fibroblasts. Analysing staining score values 
(Table l ) ,  a significantly less frequent MT immuno- 
ex ression was encountered in AGC than EGC 
(xP=8.794; df.3; P=0.033), while a trend towards this 
correlation (X2=2.881; df=l; P=0.089) was encountered 
utilising the ID-score. No relationships were found 
between other clinico-pathological data and MT 
expression in gastric carcinomas utilising either the 
staining score or the ID-score values. Moreover, the 
same results were obtained in EGC or AGC groups 
separately. 
At the time of the present study, 59 (54.6%) patients 
(7 EGC and 52 AGC) had died of disease, and 49 
(45.4%) (31 EGC and 18 AGC) were alive. The mean 
follow-up time of all patients was 60.5 months (ranging 
from 3 to 197), while for alive patients it was 101.4 
months (ranging from 36 to 197); in detail, for this latter 
group, the mean follow-up time was 100.5 months 
(ranging from 36 to 197) for EGC and 102.8 months 
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Table 1. Clinico-pathological data in 112 gastric carcinomas investigated and their correlation with MT score 
Nr. STAINING SCORE INSTENSITY-DISTRIBUTION SCORE 
0 1 2 3 Mean (+SD) 
Sex 
Age 
Tumour location 
Type of tumour 
Histological type 
Lauren class 
Histological grading 
TNM class 
Stage 
Clinical course 
Male 
Female 
S 50 
> 50 
Cardia 
Body 
Body-Antrum 
Antrum 
EGC 
AGC 
Tubular 
Papillary 
Mucinous 
Signet-ring cell 
Intestinal 
Diffuse 
Low grade 
High grade 
PT1 
P T ~  
pT3 
pT4 
PNO 
PN 1 
P N ~  
la 
Ib 
II 
llla 
lllb 
IV 
Alive 
Death for cancer 
Table 2. Detection of MT in normal gastric mucosa, carcinomas and transitional mucosa, 
STAINING SCORE INSTENSITY-DISTRIBUTION SCORE 
Positive rate 0 1 2 3 Mean (&D) 
Normal gastric mucosa 100% (22122) 0 6 8 8 5.14 (3.00) 
Gastric Carcinoma 67% (7511 12) 37 33 27 15 2.79 (3.1 5) 
Transitional Mucosa 94% (84189) 5 30 49 5 3.17 (2.21) 
(ranging from 48 to 144) for AGC. 
A univariate analysis of survival data of MT 
expression, evaluated either by staining- or ID-scores, 
failed to be of prognostic significance, even when the 
type of tumour (EGC or AGC) was used to define the 
strata. 
In the gastric peritumour mucosa, 84 of 89 (94%) 
samples were positively stained (Table 2); this 
immunoreaction was not always concordant with that 
encountered in adjacent carcinomatous elements, as 
shown in Table 3. 
When staining- and ID-scores relative to gastric 
carcinomas as well as normal and transitional mucosa 
groups were compared by the chi-square test 
(X2=50.813; df=6; P=0.0001) and the Kruskal-Wallis H- 
test (x2=17.073; df=2; P=0.0002), highly significant 
differences were found. 
Discussion 
In the present study, we have performed a systematic 
investigation on the immunohistochemical MT 
expression in normal, neoplastic and transitional gastric 
mucosa. In particular, a clear cytoplasmic andlor nuclear 
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localization of MT has been documented in glandular 
and surface mucous cells of the antrum as well as in the 
lower half of the oxyntic glands and in cells of the neck 
zone of the body in all normal gastric control specimens; 
these findings have not been reported until now in the 
Table 3. MT expression in 89 gastric carcinomas samples and 
corresponding transitional mucosa. 
GASTRIC CARCINOMA TRANSITIONAL MUCOSA 
MT + MT - 
Fig. 1. Normal gastric mucosa. An evident MT irnrnunoreactivity is 
mainly encountered in epithelial cells of the lower half of the oxyntic 
glands. MT-ABC complex, Mayer's haematoxylin nuclear counterstain. 
X 50 
stomach, although M T  immunoexpression has been 
previously described in unaffected mucosae of other 
portions of human gastrointestinal tract such as ileum 
and right or left colon (Clarkson et al., 1985; Giuffrk et 
al., 1996). The immunohistochemical presence of MT in 
normal gastric epithelium may be attributable to its 
scavenging capability; in fact, it has been claimed that 
MT is of importance in cellular defense mechanisms 
against hydroxyl free radicals (Sato and Bremner, 1993) 
as well as in the homeostatic control of Zn and Cu 
(Bremner, 1987). 
Moreover, exchange reactions between Zn-MT and 
the apoform of Zn-enzymes MT have been reported in 
vitro (Udom and Brady, 1980).  suggesting M T  is  
involved in metal-transfer reactions in vivo; therefore, 
the immunohistochemical expression of M T  in non- 
neoplastic mucous and zymogenic gastric lineages 
should also suggest a possible role of MT as a donor of 
Zn to these apoenzymes, since Zn is  required for 
synthesis of DNA and DNA-repair enzymes (Sato and 
Bremner, 1993). 
In epithelia1 compartments  of gastr ic  mucosa 
adjacent to carcinomas, a distinct MT immunostaining 
was present in 94% of samples, with a corresponding 
decrease of ID-score in comparison to that observed in 
normal control cases. Moreover, in gastric carcinomas 
the MT-positivity was encountered in only 67% of cases, 
with further reduction of ID-score. In addition, a non 
concordant MT expression between gastric carcinoma 
and its transitional mucosa was found in 31/89 cases, 28 
of which showed M T  positivity only in non-  
carcinomatous mucosa. Therefore, in the light of these 
observat ions ,  w e  are  unable  to  demonstra te  an 
overexpression of M T  in gastric carcinomas since a 
significant statistical decrease of MT scores has been 
observed moving from the normal to neoplastic gastric 
mucosa. However, in our cases of gastric carcinomas, 
the immunohistochemical evidence of MT did not show 
any correla t ion with  sex ,  age,  tumour locat ion,  
histological type or grade, TNM classes, stage and 
clinical course, while a significant decrease in MT rate 
was found in AGC in comparison to EGC, either with 
staining- or ID-scores. The possible explanations of the 
reduced MT immunoexpression in neoplastic samples in 
comparison to normal and peritumour gastric mucosa 
may be related to  dif ferent  mechanisms.  Firstly, 
neoplastic elements may utilize MT faster in order to 
have a greater availability of Zn for their turnover, even 
if a reduced M T  s to rage  cannot  be excluded.  
Additionally,  it may be hypothesized that during 
carcinogenesis other M T  isoforms are produced as a 
consequence of different gene-expression; in fact, it is 
well known that in humans 10 functional MT isoforms 
and 7 non functional ones have been demonstrated as a 
result of a family of genes (Friedline et al., 1998). 
However, the commercially available antiserum used by 
us is reactive only against a conserved N-terminal 
epi tope shared by MT-I and MT-I1 isoforms and 
therefore it is unable to distinguish between either MT-I 
Fig. 2. Gastric carcinoma. MT staining mainly localized in the cytoplasm (a); a combined nuclear/cytoplasmic reactive pattern is also seen (b, c), with a 
strong immunostaining in neoplastic elements intermingled with negative ones (b, c, d). MT-ABC complex, Mayer's haematoxylin nuclear counterstain. 
a, b, X 50; c, d, X 100 
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and MT-I1 isoforms or metal-bound and metal-free forms 
of MT or to detect other MT isoforms, as elsewhere 
suggested (Jasani and Schmid, 1997). 
The biological significance of MT expression in 
human tumours as well as its association with prognosis 
are not fully understood and conflicting explanations 
have been reported (Fresno et al., 1993; Schmid et al., 
1993; Zelger et al., 1993; Bier et al., 1994; Haerslev et 
al., 1994; Ofner et al., 1994; Douglas-Jones et al., 1995; 
Sunardhi-Widyaputra et al., 1995; Giuffre et al., 1996; 
Ohshio et al., 1996; Deng et al., 1998; McCluggage et 
al., 1998; Siu et al., 1998). In detail, a direct correlation 
between MT expression and poor clinical outcome has 
been demonstrated in some malignancies, such as 
invasive breast ductal carcinomas (Fresno et al., 1993; 
Schmid et al., 1993; Haerslev et al., 1994) and malignant 
melanomas (Zelger et al., 1993). In contrast, no 
correlation has been made with tumour differentiation or 
tumour aggressiveness in MT-positive thyroid (Nartey et 
al., 1987) and testicular embryonal carcinomas 
(Kontozoglou et al., 1987). Finally, a favourable clinical 
outcome of,,MT-positive colonic carcinoma has been 
suggested (Ofner et al., 1994), even if we have shown 
MT immunoreactivity both in stage I and I1 colorectal 
carcinomas and in advanced ones as well as  in 
corresponding metastases of the latter, excluding thus a 
relationship between MT staining and a better prognosis 
of the neoplasia (Giuffre et al., 1996). Nevertheless, in 
the present study, no significant differences in the 
survival curves regarding patients affected by gastric 
carcinomas with different MT expression were achieved, 
neither when the type of tumour was utilized as a strata 
variable. Therefore, the hypothesis the MT immuno- 
positivity in gastric carcinomas represents a prognostic 
parameter should be rejected. However, in node-positive 
(NI-N2) gastric carcinomas, it has been shown that MT 
staining did not correlate with any clinicopathological 
variables and did not affect disease-free survival 
(Monden et al., 1997), even if the method used for 
evaluating the MT immunoreactivity was over-simplistic 
and the study was only addressed to the drug resistance 
of cancer cells, without analysis of MT expression in the 
normal gastric mucosa taken from control non-neoplastic 
patients. 
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